AXP
67
-2
SWKS
38
-2
OMC
50
-16
GOOG
57
-6
SYF
86
-6
BMY
55
-8
KR
36
-6
EMR
71
-3
XEL
67
2
IBM
47
-3
RHI
57
-6
APH
65
-3
VNO
46
-13
INTU
58
-3
AMZN
61
-5
ETR
65
2
HRB
59
2
REGN
38
-2
PVH
60
-4
AMGN
42
-4
AXP
67
-2
SWKS
38
-2
OMC
50
-16
GOOG
57
-6
SYF
86
-6
BMY
55
-8
KR
36
-6
EMR
71
-3
XEL
67
2
IBM
47
-3
RHI
57
-6
APH
65
-3
VNO
46
-13
INTU
58
-3
AMZN
61
-5
ETR
65
2
HRB
59
2
REGN
38
-2
PVH
60
-4
AMGN
42
-4
Financhill
Back

Voya Global Equity Dividend and Premium Opportunity Fund Vs. Halozyme Therapeutics Industry Stock Comparison

Sell
45

IGD
Voya Global Equity Dividend and Premium Opportunity Fund

Last Price:
5.51
Seasonality Move:
-0.93%
Sell
39

HALO
Halozyme Therapeutics

Last Price:
45.65
Seasonality Move:
17.03%
Sell
45
Voya Global Equity Dividend and Premium Opportunity Fund (IGD) is a Sell

Is Voya Global Equity Dividend and Premium Opportunity Fund a Buy, Sell or Hold?

  • The current Voya Global Equity Dividend and Premium Opportunity Fund [IGD] share price is $5.51. The Score for IGD is 45, which is 10% below its historic median score of 50, and infers higher risk than normal.
  • IGD is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
39
Halozyme Therapeutics (HALO) is a Sell

Is Halozyme Therapeutics a Buy, Sell or Hold?

  • The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
  • HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.

IGD Stock Price Chart

What is Voya Global Equity Dividend and Premium Opportunity Fund's stock price today?

HALO Stock Price Chart

What is Halozyme Therapeutics's stock price today?

  • The Halozyme Therapeutics share price today is $45.65
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.

IGD Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.01 Sell
Relative Strength Index (14 RSI): 50.21 Buy
Chaikin Money Flow: -39778 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (5.43 - 5.59) Sell
Bollinger Bands (100): (5.34 - 5.64) Buy

HALO Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.02 Sell
Relative Strength Index (14 RSI): 30.2 Sell
Chaikin Money Flow: -7140517 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (49.94 - 58.56) Sell
Bollinger Bands (100): (52.16 - 60.38) Sell

IGD Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 5.51 Buy
20-day SMA: 5.49 Buy
50-day SMA: 5.55 Sell
200-day SMA: 5.31 Buy
8-day EMA: 5.5 Buy
20-day EMA: 5.5 Buy
50-day EMA: 5.51 Sell
200-day EMA: 5.36 Buy

HALO Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 57.53 Sell
20-day SMA: 54.48 Sell
50-day SMA: 56.18 Sell
200-day SMA: 48.93 Sell
8-day EMA: 55 Sell
20-day EMA: 55.41 Sell
50-day EMA: 55.64 Sell
200-day EMA: 50.73 Sell

Voya Global Equity Dividend and Premium Opportunity Fund Earnings Growth & IGD Earnings Dates

  • Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.

Halozyme Therapeutics Earnings Growth & HALO Earnings Dates

  • Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.

Voya Global Equity Dividend and Premium Opportunity Fund Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Halozyme Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):